immune checkpoint inhibition trials in mcc: advanced ... · presented by selma ugurel at 2018 asco...
TRANSCRIPT
![Page 2: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/2.jpg)
Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 3: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/3.jpg)
Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 4: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/4.jpg)
Overall survival with pembrolizumab for MCC <br />
Presented By Paul Nghiem at 2018 ASCO Annual Meeting
![Page 5: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/5.jpg)
Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 6: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/6.jpg)
Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 7: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/7.jpg)
Durable response on anti-PD-1/PD-L1 ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 8: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/8.jpg)
Which patterns of resistance do we see ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
![Page 9: Immune Checkpoint Inhibition Trials in MCC: Advanced ... · Presented By Selma Ugurel at 2018 ASCO Annual Meeting . ... Slides are the property the required reuse. Immune Checkpoint](https://reader033.vdocument.in/reader033/viewer/2022053007/5f0b290c7e708231d42f2544/html5/thumbnails/9.jpg)
Radiologic tumor response to pembrolizumab in patients<br />per viral status<br /><br /><br />
Presented By Paul Nghiem at 2018 ASCO Annual Meeting